ALTEOGEN Inc. (KOSDAQ:196170)

South Korea flag South Korea · Delayed Price · Currency is KRW
437,000
-12,000 (-2.67%)
Aug 14, 2025, 3:30 PM KST
49.40%
Market Cap 23.35T
Revenue (ttm) 151.65B
Net Income (ttm) 124.46B
Shares Out 53.44M
EPS (ttm) 2,331.25
PE Ratio 187.45
Forward PE 293.95
Dividend n/a
Ex-Dividend Date n/a
Volume 598,263
Average Volume 320,467
Open 437,500
Previous Close 449,000
Day's Range 426,000 - 444,500
52-Week Range 274,000 - 508,000
Beta 1.15
RSI 49.36
Earnings Date Aug 13, 2025

About ALTEOGEN

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the tre... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 155
Stock Exchange KOSDAQ
Ticker Symbol 196170
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.